NZ614345B2 - Method and use for measurement of nk cell activity - Google Patents
Method and use for measurement of nk cell activity Download PDFInfo
- Publication number
- NZ614345B2 NZ614345B2 NZ614345A NZ61434512A NZ614345B2 NZ 614345 B2 NZ614345 B2 NZ 614345B2 NZ 614345 A NZ614345 A NZ 614345A NZ 61434512 A NZ61434512 A NZ 61434512A NZ 614345 B2 NZ614345 B2 NZ 614345B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- interleukin
- cell
- amino acid
- seq
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 54
- 238000005259 measurement Methods 0.000 title description 5
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims abstract description 223
- 210000004369 Blood Anatomy 0.000 claims abstract description 106
- 239000008280 blood Substances 0.000 claims abstract description 106
- 210000004693 NK cell Anatomy 0.000 claims abstract description 85
- 102000004127 Cytokines Human genes 0.000 claims abstract description 66
- 108090000695 Cytokines Proteins 0.000 claims abstract description 66
- 230000003248 secreting Effects 0.000 claims abstract description 53
- 230000004936 stimulating Effects 0.000 claims abstract description 33
- 239000002158 endotoxin Substances 0.000 claims abstract description 27
- 229920000789 Polyinosinic:polycytidylic acid Polymers 0.000 claims abstract description 22
- 230000003213 activating Effects 0.000 claims abstract description 19
- 229940115272 poly I:C Drugs 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 102000000588 Interleukin-2 Human genes 0.000 claims description 64
- 108010002350 Interleukin-2 Proteins 0.000 claims description 64
- 125000000539 amino acid group Chemical group 0.000 claims description 62
- 230000002378 acidificating Effects 0.000 claims description 54
- 102000013462 Interleukin-12 Human genes 0.000 claims description 40
- 108010065805 Interleukin-12 Proteins 0.000 claims description 40
- 102000037240 fusion proteins Human genes 0.000 claims description 35
- 108020001507 fusion proteins Proteins 0.000 claims description 35
- 102000003810 Interleukin-18 Human genes 0.000 claims description 32
- 108090000171 Interleukin-18 Proteins 0.000 claims description 32
- 229940117681 Interleukin-12 Drugs 0.000 claims description 29
- 102000003812 Interleukin-15 Human genes 0.000 claims description 29
- 108090000172 Interleukin-15 Proteins 0.000 claims description 29
- 102000004965 antibodies Human genes 0.000 claims description 29
- 108090001123 antibodies Proteins 0.000 claims description 29
- 102000019355 Synucleins Human genes 0.000 claims description 26
- 108050006783 Synucleins Proteins 0.000 claims description 26
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 25
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims description 25
- 230000000087 stabilizing Effects 0.000 claims description 21
- 230000000638 stimulation Effects 0.000 claims description 19
- 238000002965 ELISA Methods 0.000 claims description 15
- 102000008070 Interferon-gamma Human genes 0.000 claims description 11
- 108010074328 Interferon-gamma Proteins 0.000 claims description 11
- 230000004913 activation Effects 0.000 claims description 11
- 102000004963 gamma-Synuclein Human genes 0.000 claims description 10
- 108090001121 gamma-Synuclein Proteins 0.000 claims description 10
- 102000014914 Carrier Proteins Human genes 0.000 claims description 6
- 108010078791 Carrier Proteins Proteins 0.000 claims description 6
- 229960003130 interferon gamma Drugs 0.000 claims description 6
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 3
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 3
- 108010055165 Chemokine CCL4 Proteins 0.000 claims 3
- 102100003170 CCL4 Human genes 0.000 claims 2
- 102100016020 IFNG Human genes 0.000 claims 2
- 101700086956 IFNG Proteins 0.000 claims 2
- 102000003799 beta-Synuclein Human genes 0.000 claims 2
- 108090000182 beta-Synuclein Proteins 0.000 claims 2
- 102000001326 Chemokine CCL4 Human genes 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 description 88
- 239000000243 solution Substances 0.000 description 24
- 210000004027 cells Anatomy 0.000 description 23
- 230000004927 fusion Effects 0.000 description 17
- 230000028327 secretion Effects 0.000 description 15
- 210000001744 T-Lymphocytes Anatomy 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 210000002540 Macrophages Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 7
- 238000004166 bioassay Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000001965 increased Effects 0.000 description 7
- 230000002757 inflammatory Effects 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 239000008188 pellet Substances 0.000 description 6
- 229920000272 Oligonucleotide Polymers 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 238000003118 sandwich ELISA Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 210000002966 Serum Anatomy 0.000 description 4
- 230000002429 anti-coagulation Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229920002676 Complementary DNA Polymers 0.000 description 3
- 229940088598 Enzyme Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 3
- 101710007374 H1-2 Proteins 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000002285 radioactive Effects 0.000 description 3
- 239000011369 resultant mixture Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 2
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 2
- 210000004443 Dendritic Cells Anatomy 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- URRBLVUOXIGNQR-HXUWFJFHSA-N [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate Chemical compound C1([C@@H](C)OC(=O)N(CCN)CC=2C=C(C(=CC=2)OCC=2C=CC=CC=2)OC)=CC=CC=C1 URRBLVUOXIGNQR-HXUWFJFHSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002147 killing Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-N,N-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000013460 EC 1.1.1.37 Human genes 0.000 description 1
- 108010026217 EC 1.1.1.37 Proteins 0.000 description 1
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000002794 Glucosephosphate Dehydrogenase Human genes 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 229940100602 Interleukin-5 Drugs 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 229920000126 Latex Polymers 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N Lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101700077124 NCAM1 Proteins 0.000 description 1
- 102100007544 NCAM1 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N [N-]=C=S Chemical compound [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000002318 immunoblotting Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 108060006184 phycobiliprotein family Proteins 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
Abstract
Disclosed is a method of measuring NK cell activity, comprising: stimulating NK cells in a whole blood sample thereby artificially activating the NK cells to generate NK cell-secreting cytokines; and measuring an amount of the NK cell-secreting cytokines in the whole blood sample. Use of at least one stimulating cytokine, lipopolysaccharide (LPS) or polyinosinic:polycytidylic acid (poly I:C) in the manufacture of a kit for measuring NK cell activity, wherein the at least one stimulating cytokine, lipopolysaccharide (LPS) or polyinosinic:polycytidylic acid (poly I:C) is provided for stimulating NK cells in a whole blood sample and thereby artificially activating the NK cells to generate NK cell-secreting cytokines, and wherein an amount of the NK cell-secreting cytokines in the whole blood sample is used to measure NK cell activity . one stimulating cytokine, lipopolysaccharide (LPS) or polyinosinic:polycytidylic acid (poly I:C) in the manufacture of a kit for measuring NK cell activity, wherein the at least one stimulating cytokine, lipopolysaccharide (LPS) or polyinosinic:polycytidylic acid (poly I:C) is provided for stimulating NK cells in a whole blood sample and thereby artificially activating the NK cells to generate NK cell-secreting cytokines, and wherein an amount of the NK cell-secreting cytokines in the whole blood sample is used to measure NK cell activity .
Description
METHOD AND USE FOR MEASUREMENT OF NK CELL ACTIVITY
CROSS-REFERENCE TO RELATEDAPPLICATION
This application claims priority to and the benefit of Korean Patent
Application No. 2011-0012983, filed on February 14, 2011, the disclosure of which is
incorporated herein by reference in its entirety.
BACKGROUND
1. Field of the Invention
The present invention relates to a method for diagnosing cancer and a
diagnosis kit using measurement ofNK cell activity.
2. Discussion of Related Art
It is known that natural killer (NK) cells take part in innate immunity to
remove pathogens and cancer cells, and secrete interferon-gamma (IFN-ã), tumor
necrosis factor-alpha (TNF-a), macrophage inflammatory protein- É â(ÌÉÑ -Éâ) and
other molecules to mediate the adaptive immunity. When NK cells encounter other
cells, the NK cells have a mechanism in which, when MHC Class 1 is not present as
in cancer cells, or a shape of MHC Class is abnormal as in cells infected with viruses,
their major histocompatibility complexes (MHCs) send signals into the NK cells to
attack these abnormal cells through their molecular actions. However, since NK cells
have been reported to have defects in functions and differentiation capacities in
various kinds of cancers, NK cell activity is closely associated with the survival of
cancer cells. Therefore, research is being widely conducted to increase the number, or
activity of NK cells for cancer immunotherapy.
Meanwhile, methods of diagnosing cancer have mainly included finding
the presence of cancer from graphic images obtained using computed tomography
(CT), magnetic resonance imaging (MRI) or X rays. However, since these tests are
generally conducted only when a patient has a strong need to undergo the tests due to
pain or inconvenience, and are performed only in certain tissues, the presence of
cancer may be overlooked. A method of determining the risk of cancer using a
blood test has been developed, but its use as a method of diagnosing cancer is limited.
This is because a patient may appear to be positive for cancer when an etiological
factor is present in the corresponding organ rather than cancer, since the method is
conducted using blood tumor markers, e.g. for prostate cancer, colon cancer, ovarian
cancer, pancreatic cancer or liver cancer. There have also been attempts to
diagnose cancer using antibodies, but such attempts are limited to certain types of
cancer.
Accordingly, there continues to be a need for new methods for
diagnosing cancers of various types.
SUMMARY OF THE INVENTION
It is therefore an object of the invention to provide a method that can be
used in the diagnosis and evaluation of cancer, as well as kits and reagents useful in
such a method.
As an aspect of the invention, there is provided a method of measuring
NK cell activity, the method comprising stimulating NK cells in a blood sample
thereby artificially activating the NK cells to generate NK cell-secreting cytokines
and measuring an amount of the NK cell-secreting cytokines in the blood sample.
In certain non-limiting embodiments, the blood sample may be a sample
of whole blood, peripheral blood mononuclear cells (PBMCs) or NK cells.
In further embodiments, the stimulation of the NK cells may be
performed by incubating the blood sample with at least one stimulating cytokine
including interleukin 2, interleukin 12, interleukin 15 and interleukin 18, or
combinations thereof, or by incubating the blood sample with lipopolysaccharides
(LPSs) or polyinosinic:polycytidylic acid (poly I:C).
The NK cell-secreting cytokines may, in certain embodiments, comprise
interferon-gamma (IFN-g ), tumor necrosis factor-alpha (TNF-a) or macrophage
inflammatory protein- 1b (MIR -1b ).
[001 1] In further non-limiting embodiments of the method, macrophage
inflammatory protein- b (MIR - 1 ) can be used as control group for comparing
activation of NK cells with that of a normal person.
In addition, the method may in certain embodiments be carried out using
at least one stimulating cytokine fused to a stabilizing peptide. For example, yet
without wishing to be limiting, the stabilizing peptide may be a C-terminal acidic tail
domain peptide of a synuclein family. In such embodiments, the stabilizing peptide
may comprise amino acid residues 103-115 (SRQ ID NO: 22), amino acid residues
114-126 (SEQ ID NO: 23), amino acid residues 119-140 (SEQ ID NO: 24) or amino
acid residues 130-140 (SEQ ID NO: 25) of the C-terminal acidic tail domain of a-
synuclein, amino acid residues 85-134 of the C-terminal acidic tail domain of b -
synuclein (SEQ ID NO: 27), amino acid residues 96-127 of the C-terminal acidic tail
domain of g -synuclein (SEQ ID NO: 29), or amino acid residues 96-127 of the C-
terminal acidic tail domain of synoretin (SEQ ID NO: 29).
In further embodiments, the step of stimulating NK cells in a blood
sample thereby artificially activating the NK cells to generate NK cell-secreting
cytokines is performed in a medium containing a carrier protein, for example a
serum albumin protein.
The method as described is particularly useful for detecting the
incidence or relapse of cancer. In such embodiments, a decrease in the amount of
the NK cell-secreting cytokines in a subject, as compared to levels in normal
individuals, is an indicator of cancer incidence or relapse.
As a further aspect of the invention there is provided a kit for measuring
NK cell activity. The kit will comprise an agent for stimulating the NK cells in a
blood sample thereby artificially activating the NK cells to generate NK cell-
secreting cytokines. In addition, the kit may be useful for carrying out the method
as described above, including for detecting the incidence or relapse of cancer.
In further non-limiting embodiments of the described kit, the NK cell-
secreting cytokine may be interferon-gamma (IFN-g ) or tumor necrosis factor-alpha
(TNF-o).
In a further embodiment, the agent for stimulating the NK cells in the
blood sample and artificially activating the NK cells to generate the NK cell-
secreting cytokines may comprise at least one stimulating cytokine, LPS or poly I:C,
the at least one stimulating cytokine including one or more of interleukin 2,
interleukin 1 , interleukin 15 and interleukin 18.
The described kit may also comprise, in certain embodiments, one or
more of the following: anti-INF-g antibody, an anti- TNF-a antibody, and an anti-
MIP- I b antibody. Without wishing to be limiting in any way, the kit may also
further comprise instructions for comparing the amount of the NK cell-secreting
cytokines in a subject to levels in normal individuals, wherein a decrease in the level
of the NK cell-secreting cytokines in the subject is an indicator of cancer incidence
or relapse.
As a further aspect of the invention, there is provided a fusion protein
comprising a cytokine bound to a C-terminal acidic tail domain peptide of a
synuclein family, the cytokine being either interleukin 2, interleukin 12, interleukin
or interleukin 18.
In certain non-limiting embodiments of the described fusion protein, the
C-terminal acidic tail domain peptide of the synuclein family may comprise amino
acid residues 103-115 (SEQ ID NO: 22), amino acid residues 114-126 (SEQ ID NO:
23), amino acid residues 119-140 (SEQ ID NO: 24) or amino acid residues 130-140
(SEQ ID NO: 25) of the C-terminal acidic tail domain of a-synuclein, amino acid
residues 85-134 of the C-terminal acidic tail domain of b -synuclein (SEQ ID NO:
27), amino acid residues 96-127 of the C-terminal acidic tail domain of g -synuclein
(SEQ ID NO: 29), or amino acid residues 96-127 of the C-terminal acidic tail
domain of synoretin (SEQ ID NO: 29).
Compositions comprising the above-described fusion protein are also
provided.
In addition, cancer diagnosis kits comprising either the above- described
fusion proteins or the above-described compositions are also provided herein.
The cancer diagnosis kit, as described above, may in certain non-
limiting embodiments also include at least one antibody among the following: an
anti-INF-g antibody, an anti- TNF-a antibody and an anti-MIR -I b antibody.
There is also provided herein a polypeptide comprising an amino acid
sequence having at least 80% identity to an amino acid sequence of SEQ ID NO: 2,
SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10. Without
wishing to be limiting, the polypeptide may have a higher percent identity, including
81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99% or 100% identity to the sequences of SEQ ID NO: 2,
SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 10.
Oligonucleotides encoding the above-described fusion proteins and
polypeptides are also provided. For instance, an oligonucleotide is provided
comprising a nucleic acid sequence with at least 80% identity to a nucleic acid
sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ
ID NO: 9, or the complement thereof. Such oligonucleotides may, without
limitation, have a higher percent identity, including 81%, 82%, 83%, 84%, 85%,
86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or
100% identity to the sequences of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5,
SEQ ID NO: 7, or SEQ ID NO: 9, or the complementary sequences thereof.
Vectors comprising the oligonucleotides described above are also
provided, as are host cells comprising such vectors or oligonucleotides.
BRIEF DESCRIPTION OF THE DRAWINGS
The above and other objects, features and advantages of the present
invention will become more apparent to those of ordinary skill in the art by
describing in detail exemplary embodiments thereof with reference to the drawings,
in which:
is a schematic view showing the fusion products of an SP peptide
fused either with the N terminus or C terminus of a cytokine, including hIL2, hIL12,
hIL15 and hIL18.
is a photograph showing the electrophoresis results of the
purified SP fusion proteins.
shows the NK cell activity artificially activated in a normal
person through analysis of an amount of generated interferon-g , when the NK cells
are stimulated by single cytokine (FIG 3A) or combined cytokines (FIGS. 3B -3D).
is a graph showing cytokines secreted from artificially activated
NK cells through sandwich ELISA.
shows a comparison of the protein activity (A) and stability (B)
between SP IL-2 and IL-2.
shows the activity of NK cells in normal persons and cancer
patients which are treated with SP IL-2 (10ng/ml)(Condition A), and SP IL-
2(5ng/ml)+IL-12(5ng/ml)(Condition B), separately.
is a graph showing the capability of NK cells to secrete
interferon-g in T cells, NK cells, whole blood and PBMC according to the stimulus
ofIL2.
is a graph showing a variation in amount of interferon-g secreted
from NK cells of a normal person, as stimulated by LPS.
is a graph showing a variation in capability of NK cells to secrete
interferon-g according to concentrations of IL12 and IL15 treated and difference in
compositions of media.
is a graph showing a variation in amount of secreted interferon-g
according to the progress stage of cancer.
shows the results of analysis of interferon-g generated from NK
cells of a normal person stimulated by cytokines using an ELISA plate.
shows the flow cytometric results of whole blood from normal
persons stimulated by cytokines.
DETAILED DESCRIPTION
The present invention is directed to a method, kit, and reagents for
diagnosing cancer incidence using the interrelationship of cancer and NK cells.
For this purpose, there is provided a method of measuring NK cell
activity comprising stimulating NK cells in a blood sample thereby artificially
activating the NK cells to generate NK cell-secreting cytokines, and measuring an
amount of the NK cell-secreting cytokines in the blood sample.
The present inventors have found that, based on the an observation that
NK cell activity is reduced in cancer patients, the incidence of cancer may be
primarily screened by measuring NK cell activity. The method described herein is
capable of determining whether or not the NK cells function normally by giving an
artificial stimulus to the NK cells, and measuring an activation level of the NK cells
by detecting changes in the amount of NK cell-secreting cytokines present in a blood
sample, which differs from other methods which simply measure the number of the
NK cells or an amount of cytokines originally present in the blood sample. For
example, in a conventional method of measuring an activation level of the NK cells,
a Cr release assay has been used as a method of measuring the target-specific
cytotoxicity. However, when the NK cell activity is measured in this manner, a
radioactive isotope should be used, and measurement and analysis are difficult,
complicated and costly. Therefore, the assay is unsuitable for use in primary
cancer screening/testing methods which can simply diagnose the incidence of cancer.
On the other hand, according to the present invention, since NK cell activity may be
measured by stimulating the NK cells to generate NK cell-secreting cytokines and
quantifying the generated NK cell-secreting cytokines, a subject in which NK cell
activity is reduced may be advantageously screened as a subject suffering from
cancer or at risk of suffering from cancer.
According to the present invention, the blood sample may include, but is
not limited to, whole blood, peripheral blood mononuclear cells (PBMCs) and NK
cells, which are taken from the subject. The PBMCs or NK cells may be used
intact instead of the whole blood, but the use of the whole blood may be
advantageous in certain embodiments due to simpler methodology and reduced costs.
Meanwhile, in the present invention, the term "subject" refers to a
mammal that is suspected of suffering from cancer or having a relapse of cancer, or
that wishes to determine the incidence or relapse of cancer.
The NK cells present in the blood sample are generally present in an
inactivated state. According to the present invention, at least one cytokine,
lipopolysaccharide (LPS) or polyinosinic:polycytidylic acid (poly I:C) may be used
as an agent, also referred to herein as an agonist or activator, that serves to stimulate
such NK cells in the blood sample and artificially activate the NK cells to generate
NK cell-secreting cytokines. Here, the cytokine used for activating NK cells may
be interleukin 2, interleukin 12, interleukin 1 and interleukin 18, or combinations
thereof. The interleukin 2, the interleukin 12, the interleukin 15, the interleukin 18,
the LPS or the poly I:C are widely known in the art to be stimulated to generate the
NK cell-secreting cytokines. Therefore, according to one exemplary embodiment
of the present invention, the stimulation of the NK cells may be performed by
incubating the blood sample with the at least one cytokine, including interleukin 2,
interleukin 12, interleukin 15 and/or interleukin 18, or by incubating the blood
sample with LPS or poly I:C.
In one non-limiting embodiment, the stimulation of the NK cells may be
performed by incubating the blood sample with Interleukin 2. Interleukin 2 is one
of the cytokines secreted by the T cells, and is known to be associated with
activation of the NK cells by T cells in an in vivo adaptive immune response. Also,
the interleukin 2 is a cytokine that is generally widely used to activate the NK cells
in vitro. Therefore, the stimulation of the NK cells may be performed by
incubating the blood sample with the interleukin 2.
In another non-limiting embodiment, the stimulation of the NK cells
may be performed by incubating the blood sample with Interleukin 2 and Interleukin
12. In case of cancer patients in early stage, the activity of T cells may be high
even though the activity of NK cells is low. In contrast, in case of cancer patients
in late stage, the activity of T cells as well as NK cells may be low. Interleukin 12
takes part in activating T cells as well as NK cells. Thus, if interleukin 12 with
interleukin 2 is treated, cytokines secreted due to stimulation of T cells are added to
the cytokine secreted from NK cells. Therefore, it is possible to evaluate total level
of immunity as well as anticancer immunity of NK cells, and use this level as a
marker representing degree of process of cancer or prognosis of cancer treatment.
The interleukin 15 and the interleukin 18 are cytokines secreted by activated
dendritic cells and macrophages, and induce activation and growth of the NK cells
during an in vitro innate immune response. In particular, when the interleukin 12 is
combined with the interleukin 15 or the interleukin 18, a relatively small amount of
the interleukin 12 may be used to stimulate the secretion of the NK cell-secreting
cytokines in the NK cells. Therefore, the stimulation of the NK cells may be
effectively performed by incubating the blood sample with the interleukin 12 and the
interleukin 15, or with the interleukin 1 and the interleukin 18.
According to the present invention, a numerical value of the NK cell-
secreting cytokines is used as a measure to evaluate NK cell activity. In the present
invention, "NK cell-secreting cytokines" refers to cytokines secreted from NK cells,
in particular cytokines from activated NK cells by artificial stimulation. In one
embodiment, the NK cell-secreting cytokines are at least one cytokine selected from
the group of interferon-gamma (IFN-g ), tumor necrosis factor-alpha (TNF-a) and
macrophage inflammatory rGq ΐ h -I b (MIR -I b ). The interferon-g is secreted by NK
cells, dendritic cells, Tc cells, Thl cells, and the like, and is known to be a cytokine
that takes an important role in innate immunity and adaptive immunity for the
control of cancer. Also, tumor necrosis factor-alpha (TNF-a) kills cancer cells and
further take part in killing external intruder such as bacteria, inducing activation of T
cells, and playing a role as a supplementary factor for producing antibody from B
cells. Therefore, for example, when the numerical value of the interferon-g or
tumor necrosis factor-alpha is smaller than that of the interferon-g or tumor necrosis
factor-alpha from a normal person, this indicates that the NK cell activity for the
control of cancer is problematic. Therefore, it is possible to determine NK cell
activity by comparing an amount of the interferon-g or tumor necrosis factor-alpha
secreted from the artificially activated NK cells with an amount of the interferon-g or
tumor necrosis factor-alpha from the normal person.
Meanwhile, macrophage inflammatory protein- I b (MIR -I b ) can be used
as control group for comparing activation of NK cells. As shown in the following
examples, the numerical value of macrophage inflammatory protein- I b (MIR -I b ) is
similarly high in both normal persons and cancer patients. Thus, macrophage
inflammatory protein- I b (MIR -I b ) can be used for analyzing the activity of NK cells
in normal persons and cancer patients, or can be used as an control group for analysis
using a cancer diagnosis kit.
Quantification of the NK cell-secreting cytokines may be performed by
any methods known in the art, but the present invention is not limited thereto. For
example, the quantification of the interferon-g may be performed using an interferon-
g enzyme-linked immunosorbent assay (Interferon-g ELISA).
Meanwhile, at least one cytokine including interleukin 2, interleukin 12,
interleukin 15 or interleukin 18, which is used as an agent that serves to stimulate the
NK cells in the blood sample and artificially activate the NK cells to generate NK
cell-secreting cytokines, may be in the form of a fusion protein with a stabilizing
peptide.
The interleukin 2, the interleukin 1 , the interleukin 15 or the interleukin
18 in the form of a fusion protein with a stabilizing peptide may provide similar
biological activity and high storage stability, compared to those of wild-type
interleukin 2, interleukin 12, interleukin 15 or interleukin 18. For example, when
the cytokine is bound to such a stabilizing peptide, the cytokine has an innate activity
while maintaining stability despite changes in environment, such as freeze-drying.
The stabilizing peptide may be bound to the N- or C-terminus of the
interleukin 2, interleukin 12, interleukin 15 or interleukin 18, and preparation of such
a fusion protein may be performed using known methods of preparing fusion
proteins.
According to one exemplary embodiment, a C-terminal acidic tail
(acidic tail amino acid sequence of alpha-synuclein, ATS) domain peptide of a
synuclein family may be used as the stabilizing peptide that can be bound to the
interleukin 2, interleukin 12, interleukin 15 or interleukin 18, but the present
invention is not limited thereto. Korean Registered Patent No. 10-0506766
discloses that an ATS peptide endows a fusion partner protein with a resistance
against environmental stresses.
According to one exemplary embodiment, the stabilizing peptide that
may be used herein includes a stabilizing peptide selected from amino acid residues
103-1 15, amino acid residues 114-126, amino acid residues 119-140 and amino acid
residues 130-140 of the C-terminal acidic tail domain of a-synuclein, amino acid
residues 85-134 of the C-terminal acidic tail domain of b -synuclein, amino acid
residues 96-127 of the C-terminal acidic tail domain of g -synuclein, and amino acid
residues 96-127 of the C-terminal acidic tail domain of synoretin. In the present
invention, an amino acid sequence of an ATS peptide, an ATS peptide and a method
of preparing a fusion protein including the same may be performed using a method
disclosed in Korean Registered Patent No. 10-0506766. Referring to the following
Examples, it is shown that the interleukin 2, interleukin 12, interleukin 15 or
interleukin 18 fused with the ATS peptide is highly stable, and expresses a similar
activity to a wild-type version when the cytokine is activated by T lymphocyte.
In one embodiment, the step of stimulating NK cells in a blood sample
thereby artificially activating the NK cells to generate NK cell-secreting cytokines
can be performed in medium containing a carrier protein. The carrier protein plays
a role for stabilizing the cytokines such as interleukin 2, interleukin 12, interleukin
or interleukin 18 which are used as the agent for stimulating the NK cells in the
blood sample and artificially activating the NK cells to generate the NK cell-
secreting cytokines, and thereby inducing NK cells to produce more NK cell-
secreting cytokines. The carrier protein may, in certain embodiments, be bovine
serum albumin or human serum albumin, but is not limited thereto.
Meanwhile, the method of measuring NK cell activity may be used to
screen the incidence or relapse of cancer.
The NK cell activity may be measured by comparing an amount of NK
cell-secreting cytokines secreted from the artificially activated NK cells with an
amount of NK cell-secreting cytokines from the normal person. In this case, when
the amount of the NK cell-secreting cytokines is smaller than that of the NK cell-
secreting cytokines from the normal person, the NK cell activity is considered to be
reduced. Therefore, it is possible to assess the risk of cancer or a relapse of cancer.
When NK cell activity is reduced compared to the normal person, a subject may be
primarily classified as a patient suspected of suffering from cancer or a patient
having a relapse of cancer. Also, the incidence or relapse of cancer may be
diagnosed through an additional diagnostic method such as CT, MRI or positron
emission tomography (PET) for usually performed diagnosis of cancer, and through
a final tissue test. Although the method according to the present invention is not a
method of definitively diagnosing cancer, the method has a good merit in that the
incidence or relapse of cancer may be primarily screened using blood.
In addition, the present invention provides a kit for measuring NK cell
activity, including an agent, such as an agonist or activator that serves to stimulate
the NK cells in a blood sample and artificially activate the NK cells to generate NK
cell-secreting cytokines. Such a kit for measuring NK cell activity may be used to
readily perform the above-mentioned method of measuring NK cell activity.
In the kit for measuring NK cell activity, the agent that serves to
stimulate the NK cells and artificially activate the NK cells to generate NK cell-
secreting cytokines may be at least one cytokine, LPS or poly I:C, and the cytokine
may be selected from the group consisting of interleukin 2, interleukin 12,
interleukin 5 and interleukin 18.
In addition to the agent that serves to stimulate the NK cells and artificially
activate the NK cells to generate the NK cell-secreting cytokines such as interferon-g ,
such a cancer diagnosis kit may include additional components for measurement of
NK cell activity, for example an antibody for quantifying the NK cell-secreting
cytokines, and a substrate. In one embodiment, the kit of the present invention
further comprises at least one antibody selected from the group of an anti-INF-g
antibody, anti- TNF-a antibody and anti- I R -I b antibody.
The antibody in the kit according to the present invention may be fixed
onto a solid substrate. The antibody may be fixed using various methods as
described in the literature (Antibodies: A Laboratory Manual, Harlow & Lane; Cold
Spring Harbor, 1988). The suitable solid substrate may include a cell culture plate,
an ELISA plate, a tube and a polymeric film. In addition, the solid substrate
includes a bar, a synthetic glass, an agarose bead, a cup, a flat pack, or other films or
coatings that are supported by or attached to the solid supports.
Also, the kit according to the present invention may include a reagent
used for immunological analysis with an antibody selectively recognizing the NK
cell-secreting cytokiness such as interferon-g . The immunological analysis may
include all methods that can measure the binding of an antigen to the antibody
according to the present invention. Such methods are known in the art, and include,
for example, immunocytochemistry and immunohistochemistry, a
radioimmunoassay, ELISA, immunoblotting, a Farr assay, precipitin reaction, a
turbidimetric method, immunodiffusion, counter-current electrolysis, single-radical
immunodiffusion and immunofluorescence.
The reagent used for the immunological analysis includes a suitable
carrier, a label capable of generating a detectable signal, a dissolving agent, and a
detergent. Also, when a labeling material is an enzyme, the reagent may include a
substrate, which can measure the enzymatic activity, and a reaction stopping agent.
The suitable carrier may include, but is not limited to, a soluble carrier, for example
one of physiologically available buffers known in the art (for example, PBS) or an
insoluble carrier, for example a polymer such as magnetic particles obtained by
coating a metal onto polystyrene, polyethylene, polypropylene, polyester,
polyacrylonitrile, a fluorine resin, crosslinkable dextran, polysaccharide and latex,
and other papers, glasses, metals, agarose, and combinations thereof.
As the label that can generate a detectable signal, an enzyme, a
fluorescent material, a luminescent material and a radioactive material may be used.
As the enzyme, peroxidase, alkaline phosphatase, b -D-galactosidase, glucose oxidase,
malate dehydrogenase, glucosephosphate dehydrogenase, invertase and the like
may be used, and isothiocyanate fluorescein or phycobiliprotein may be used as the
fluorescent material, isolucinol or lucigenin may be used as the luminescent material,
and C or H may be used as the radioactive material. In addition to the
14 3
exemplary materials, however, any materials that can be used for immunological
analysis may be used herein.
In addition, the present invention provides a fusion protein including a
cytokine bound to a C-terminal acidic tail domain peptide of a synuclein family.
Here, the cytokine may be interleukin 2, interleukin 12, interleukin 15 or interleukin
18. As described above, such a fusion protein may be used as the agent that serves
to stimulate the NK cells and artificially activate the NK cells to generate NK cell-
secreting cytokines, and provides higher stability despite changes in environments
such as freeze-drying or long-term storage, compared to a wild-type interleukin 2,
interleukin 12, interleukin 15 or interleukin 18.
According to one exemplary embodiment, the fusion protein may be a
fusion protein in which the interleukin 2 is bound to the C-terminal acidic tail
domain peptide of the synuclein family.
According to another exemplary embodiment, the fusion protein may be
a fusion protein in which the interleukin 12 is bound to the C-terminal acidic tail
domain peptide of the synuclein family.
According to still another exemplary embodiment, the fusion protein
may be a fusion protein in which the interleukin 15 is bound to the C-terminal acidic
tail domain peptide of the synuclein family.
According to yet another exemplary embodiment, the fusion protein may
be a fusion protein in which the interleukin 18 is bound to the C-terminal acidic tail
domain peptide of the synuclein family.
In the fusion protein, the C-terminal acidic tail domain peptide of the
synuclein family may also be selected from amino acid residues 103-1 15, amino acid
residues 114-126, amino acid residues 119-140 and amino acid residues 130-140 of
the C-terminal acidic tail domain of a-synuclein, amino acid residues 85-134 of the
C-terminal acidic tail domain of b -synuclein, amino acid residues 96-127 of the C-
terminal acidic tail domain of g -synuclein, and amino acid residues 96-127 of the C-
terminal acidic tail domain of synoretin.
In addition, the present invention provides the use of the fusion protein
for activating the NK cells. As described above, such a fusion protein may be used
to activate NK cells in blood to promote secretion of NK cell-secreting cytokines.
Therefore, the present invention provides a composition for activating
NK cells. Here, the composition includes at least one fusion protein selected from
the group consisting of interleukin 2 bound to a C-terminal acidic tail domain peptide
of a synuclein family, interleukin 12 bound to the C-terminal acidic tail domain
peptide of the synuclein family, interleukin 15 bound to the C-terminal acidic tail
domain peptide of the synuclein family, and interleukin 18 bound to the C-terminal
acidic tail domain peptide of the synuclein family.
According to one exemplary embodiment, the C-terminal acidic tail
domain peptide of the synuclein family may be selected from amino acid residues
103-1 15, amino acid residues 114-126, amino acid residues 119-140 and amino acid
residues 130-140 of the C-terminal acidic tail domain of a-synuclein, amino acid
residues 85-134 of the C-terminal acidic tail domain of b -synuclein, amino acid
residues 96-127 of the C-terminal acidic tail domain of g -synuclein, and amino acid
residues 96-127 of the C-terminal acidic tail domain of synoretin.
Meanwhile, the composition for activating NK cells may include a
buffer capable of keeping and storing the fusion protein, in addition to the cytokines
fused with the stabilizing peptide.
Furthermore, the present invention provides a cancer diagnosis kit
including at least one fusion protein selected from the group consisting of interleukin
2 bound to a C-terminal acidic tail domain peptide of a synuclein family, interleukin
12 bound to the C-terminal acidic tail domain peptide of the synuclein family,
interleukin 15 bound to the C-terminal acidic tail domain peptide of the synuclein
family, and interleukin 18 bound to the C-terminal acidic tail domain peptide of the
synuclein family. As described above, when a blood sample taken from a subject
is incubated with the fusion protein, the NK cells in the blood sample are activated.
Therefore, NK cell activity in the subject may be measured by quantifying
interferon- g generated by activation of the NK cells, thereby primarily diagnosing
cancer by classifying subjects who have a lower NK cell activity than that of a
normal person as patients who are at risk of suffering from cancer or having a relapse
of cancer.
According to one exemplary embodiment, the C-terminal acidic tail
domain peptide of the synuclein family may be selected from amino acid residues
103-1 15, amino acid residues 114-126, amino acid residues 119-140 and amino acid
residues 130-140 of the C-terminal acidic tail domain of a-synuclein, amino acid
residues 85-134 of the C-terminal acidic tail domain of b -synuclein, amino acid
residues 96-127 of the C-terminal acidic tail domain of g -synuclein, and amino acid
residues 96-127 of the C-terminal acidic tail domain of synoretin.
In addition to the fusion protein, such a cancer diagnosis kit may include
additional components used to perform the diagnostic method according to the
present invention, for example an antibody for quantifying the NK cell-secreting
cytokines, and a substrate. These components have been described above in
connection with the kit for measuring NK cell activity. Instructions for using these
components in the above-described method may also be included in the kit.
It will be apparent that these and other features, aspects, and advantages
of preferred embodiments of the present invention will be more fully described in the
following examples. It is also to be understood that these examples are provided
for the purpose of illustration only, and are not intended to limit the scope of the
invention. One skilled in the art will understand that other equivalents and
modifications can be made without departing from the scope of the invention as
claimed.
EXAMPLES
Preparative Example 1: Construction of Expression Vector with Stabilizing
peptide-IL Fusion Protein
In order to prepare IL-2, IL-12 IL-15 or IL-18 fused with a stabilizing
peptide, an expression vector was constructed. A peptide containing amino acid
residues 119-140 of the a-synuclein (SEQ ID NO: 23; hereinafter, referred to as
"SP") was used as the stabilizing peptide. cDNAs of IL2, IL12p35, IL12p40, IL15
and IL-18 were obtained by isolating total RNA from human lymphocytes using a
total RNA extraction kit (Invitron Biotechnology) and reverse-transcribing the total
RNA using reverse transcriptase (Invitrogen). The resultant cDNA was used as a
template, and amplified with PCR using the following primers specific to each
cDNA gene:
IL2BamHl-F : ACA GGATCC CCTACTTCAAGTTCT (SEQ ID NO:ll)
IL2Xho-R : CACTCTCGAGT CAAGT CA GTGTTG GA T (SEQ ID NO:12)
IL12-p40BamH : GTGGATCCATATGGGAACTGAAGAAAGATG (SEQ ID NO:13)
IL12-p40CT-His : ATGGTGATGATGACTGCAGGGCACAGATGCCC (SEQ ID
NO: 14)
IL12-p35BamH : GTGGATCCAGAAACCTCCCCGTGGC (SEQ ID NO: 15)
IL12-p35CT-His : ATGGTGATGATGGGAAGCATTCAGATAGC (SEQ ID NO: 16)
IL15Nde : GAGTCAAGCATATGAACTGGGTGAATGTAA
(SEQ ID NO: 17)
IL15BamH-R : GTGGAT CCA GAAGT GT TGAT GAAC (SEQ ID NO: 18)
IL18BamH : GTGGATCCTACTTTGGCAAGCTTG (SEQ ID NO: 19)
IL18EcoRl : AGACTGGAATTCCTAGTCTTCGTTTTG (SEQ ID NO:20).
is a schematic view showing the constructs of the fusion products
of SP with the noted cytokines, including IL2, IL12p35, IL12p40, IL 15 and IL-18.
As illustrated in the figure, an SP-WL2 fusion product was constructed by
sequentially sub-cloning genes coding for PCR-amplified hIL2 and amino acid
residues 119-140 of the a-synuclein into a pRSETA expression vector. An SP-
hIL12p40 fusion product was constructed by sequentially sub-cloning genes coding
for PCR-amplified hIL12p40 and amino acid residues 119-140 of the a-synuclein
into a pVL1393 expression vector. An SP-hIL12p35 fusion product was
constructed by sequentially sub-cloning genes coding for PCR-amplified hIL12p35
and amino acid residues 119-140 of the a -synuclein into a pVL1393 expression
vector. An ML15-SP fusion product was constructed by sequentially sub-cloning
genes coding for PCR-amplified hIL15 and amino acid residues 119-140 of the a-
synuclein into a pRSETA expression vector. An SP-hIL18 fusion product was
constructed by sequentially sub-cloning genes coding for PCR-amplified hIL18 and
amino acid residues 19-140 of the a -synuclein into a pRSETA expression vector.
Sequences of all the constructs were confirmed through DNA sequencing.
Nucleic acid and amino acid sequences of the SP-hIL2 fusion product
are set forth in SEQ ID NOS: 1 and 2, respectively. Nucleic acid and amino acid
sequences of the SP-hIL12p40 fusion product are set forth in SEQ ID NOS: 3 and 4,
respectively. Nucleic acid and amino acid sequences of the SP-hIL12p35 fusion
product are set forth in SEQ ID NOS: 5 and 6, respectively. As shown in a
6X His-tag sequence is contained in each vector for the purpose of isolation and
purification of the SP-hIL12p40 fusion product and the SP-hIL12p35 fusion product,
which were expressed by viruses. Nucleic acid and amino acid sequences of the
hIL15-SP fusion product are set forth in SEQ ID NOS: 7 and 8, respectively. Also,
nucleic acid and amino acid sequences of the SP-ML18 fusion product are set forth
in SEQ ID NOS: 9 and 10, respectively.
Preparative Example 2; Expression and Purification of Recombinant SP
Fusion Protein
The expression vector constructed to express the recombinant SP-WL2
protein was transformed into Escherichia coli BL21(DE3)RIPL (Invitrogen), and
incubated. A culture solution was centrifuged at 10,000 rpm for 10 minutes to
obtain a cell pellet. The cell pellet was re-suspended in phosphate buffered saline
(PBS, pH 7.4), and then homogenized by sonication. The SP fusion protein
expressed in an insoluble form in E. coli was subjected to a refolding procedure, and
then purified using an ion-exchange resin.
The two expression vectors constructed to express the recombinant SP-
hIL12 protein were transfected into insect cell lines, sf21 cells, to produce viral
culture solutions, respectively. The two resultant viral culture solutions were
transfected into an insect sf21 cell line at the same time to produce a heterodimeric
IL12p70 protein in which the IL12p40 was bound to the IL12p35, which was then
purified.
The expression vector constructed to express the recombinant hIL15-SP
protein was transformed into E. coli BL21(DE3)RIPL (Invitrogen), and then
incubated. A culture solution was centrifuged at 10,000 rpm for 10 minutes to
obtain a cell pellet. The cell pellet was re-suspended in PBS (pH 7.4), and then
homogenized by sonication. The SP fusion protein expressed in a soluble form in
E. coli was purified using an ion-exchange resin.
The expression vector constructed to express the recombinant SP-hIL18
protein was transformed into E. coli BL21(DE3)RIPL (Invitrogen), and then
incubated. A culture solution was centrifuged at 10,000 rpm for 10 minutes to
obtain a cell pellet. The cell pellet was re-suspended in PBS (pH 7.4), and then
homogenized by sonication. The SP fusion protein expressed in a soluble form in
E. coli was purified using an ion-exchange resin.
The purified SP fusion protein (3ug) was electrophoresed using 15%
SDS-PAGE to confirm a final purified protein ( (a) SP-ML2 protein (ATGen,
Cat# ATGK04), (b) IL15-SP protein (ATGen, Cat# ATGK06), and (c) SP-IL18
protein (ATGen, Cat# ATGK07)).
Experimental Example 1: Confirming kinds of cytokines capable of activating
NK cells in whole blood
1 ml of whole blood from a normal person and 1 ml of an RPMI1640
medium were put into a 24-well cell culture plate, mixed with 10 ng/ml of each of
recombinant human interleukins IL-2, IL-12, IL-15 and IL-18, and then cultured for
24 hours. After the 24-hour culture, a supernatant was taken, and an amount of
interferon- g in the supernatant was measured using a sandwich ELISA method (). As a result, cytokines secreted by NK cells in the blood sample of the normal
person were not detected due to their trace amount, but when the blood sample was
treated with at least one of IL-2, IL-12, IL-15 and IL-18, a level of cytokines
secreted by the NK cells in the blood sample was increased. When the blood
sample was treated with an NK cell stimulator alone, it was seen that a level of
interferon- g in the blood sample was increased especially in the ILtreated and IL-
12-treated groups ().
Also, 1 ml of whole blood from a normal person and 1 ml of an
RPMI1640 medium were put into a 24-well cell culture plate, treated with various
combinations of recombinant human interleukins as shown in (each 10
ng/ml), and cultured for 24 hours. After the 24-hour culture, a supernatant was
taken, and a level of interferon- g was measured in the same manner as described
above. When the whole blood was treated with various combinations of NK cell
stimulators, it was seen that a level of interferon- g was increased especially in the
presence of IL-2+IL-12 ().
Further, in order to measure a level of interferon- g after the treatment
with a combination of IL-12 and IL-15, the whole blood was treated with a
concentration of the NK cell stimulator as shown in , and cultured for 24
hours. After the 24-hour culture, a supernatant was taken, and a level of interferon-
g was measured in the same manner as described above.
In order to measure a level of interferon- g after the treatment of a
combination of IL-12 and IL-18, the whole blood was also treated with a
concentration of the NK cell stimulator as shown in , and then cultured for
24 hours. After the 24-hour culture, a supernatant was taken, and a level of
interferon- g was measured in the same manner as described above.
Experimental Example 2: Confirming kinds of cytokines secreted from NK
cells artificially activated with IL-2
Whole blood samples were taken from 6 1 normal persons and 50 cancer
patients. 1 ml of the whole blood and 1 ml of an RPMI1640 medium were put into
a 24-well cell culture plate, treated with 10 ng/ml of a recombinant human
interleukin SP IL-2, and then cultured for 24 hours. After the 24-hour culture, a
supernatant was taken, and levels of interferon- g , TNF-a and MIP- I b were then
measured using a sandwich ELISA method. As a result, it was confirmed that the
interferon- g and TNF-a were secreted from the whole blood of the normal person in
a smaller amount than that of the cancer patient, but the MIP- I b was secreted from
the whole blood samples of the normal person and the cancer patient, as shown in
In the case of in vitro diagnostic reagents used in a disease test, a variety
of validation techniques were used. In general, a normal range and a cut-off assay
were used herein. The normal range is a reference range which is used to measure
an average value and a standard deviation of each group of samples, and the cut-off
assay is a method of measuring clinical sensitivity and specificity by calculating an
estimated value of an in vitro diagnostic reagent. The clinical sensitivity means a
probability of being proven to show positive results of a diagnostic test when a
patient suffers from a disease, and the clinical specificity means a probability of
being proven to show negative results of the diagnostic test when a patient does not
suffer from a disease.
Assume that, when a cut-off value is more than 10% and less than 10%,
the cut-off value is set to positive and negative values, respectively. Then, the
clinical sensitivity and clinical specificity were measured using a cut-off assay.
The results are listed in Table 1.
Table 1
In the groups of cancer patients and normal persons, IFN-g was
measured to have a sensitivity of 98.4% and a specificity of 98%. Although TNF-a
was measured to have a sensitivity of 90.9% and a specificity of 69%, which were
lower than those of IFN-g , cancer diagnostic kits developed up to date have a
specificity of at most 20 to 30%. Thus, it is expected that the TNF-a having a
specificity of approximately 70% or more may also be used as a marker for cancer
diagnostic kits to measure the NK cell activity.
Experimental Example 3; Comparison of stabilities of SP IL-2 and IL-2
In order to compare the stabilities of SP IL-2 and IL-2, whole blood
samples were taken from two persons. 1 ml of each obtained whole blood sample
and 1 ml of an RPMI1640 medium were put into a 24-well cell culture plate, and SP
IL-2 and IL-2 were then added, thoroughly mixed, and then cultured for 24 hours.
After the 24-hour culture, a supernatant was taken, and a level of interferon- g was
measured using a sandwich ELISA method. From the results of the IL-2 and SP
IL-2 activity assays, it was seen that there was no difference in activities of the two
proteins (). However, when the whole blood was treated with SP IL-2
rather than IL-2 under the whole blood culture conditions, respectively, it could be
confirmed that the NK cells were activated by SP IL-2, thereby increasing a level of
the interferon- g (). This indicates that there is no difference in activities of
the two proteins but the stability of IL-2 is increased due to application of SP.
Experimental Example 4: Comparison of NK cell activity from normal
persons and cancer patients according to conditions for simulation of NK cells
1 ml of each of whole blood samples taken from 20 normal persons and
48 terminal (stage 3 to 4) cancer patients, and 1 ml of an RPMI1640 medium were
put into a 24-well culture plate, each sample was divided into two sub-groups, and
the sub-groups were treated with SP IL-2 (10 ng/ml) (Condition A) and SP IL-2 (5
ng/ml) + IL-12 (5 ng/ml) (Condition B), respectively, and then cultured for 24 hours.
After the culture, a supernatant was taken, and a level of interferon- g was measured
using a sandwich ELISA method.
As a result, it was seen that approximately 90% of the normal persons
had a high interferon-g level but most of the cancer patients had a low interferon- g
level in the case of Condition A, as shown in In the case of Condition B, it
was also seen that the normal persons had a high interferon-g level but most of the
cancer patients had a low interferon-g level. However, the high interferon- g level
was higher in the cancer patients in the case of Condition B, compared to the case of
Condition A. When the whole blood sample is treated with SP IL-2 alone, only the
NK cells are specifically activated (see the following Experimental Example 5 and
, but the NK cells are likely to be activated together with T cells when the
whole blood sample is treated with a combination of SP IL-2 and IL-12, and thus a
level of interferon- g is likely to be increased by activation of the T cells. Therefore,
a high interferon- g level is considered to be possible to observe in some of the cancer
patients in which the T cell activity remains. When the cancer patients had a low
interferon- g level even when treated with Condition B, it could be deduced that the
anticancer immunity of the NK cells and the general systemic immunities were
decreased in the cancer patients. This is considered to be used as an important
marker for determining the cancer progression or prognosis.
Experimental Example 5: Comparison of NK Cell Activity from Normal
Persons and Cancer Patient by IL2 according to Type of Blood Samples
In order to determine the difference in interferon- g secretion capability
by IL2 according to the type of blood samples from normal persons, the following
experiment was performed (a) The interferon- g secretion capability of the NK
cells on 1 ng/ml of IL2 from the T cells, (b) the interferon- g secretion capability of
the NK cells on 1 ng/ml of IL2 from the NK cells, (c) the interferon- g secretion
capability of the NK cells on 1 ng/ml of IL2 from the whole blood, and (d) the
interferon- g secretion capability of the NK cells according to concentration of IL2
from the PBMC were measured. The results are shown in The
interferon-g was measured in the same manner as described above. As a result,
since the amount of the interferon-g secreted by activation of the IL2 in the T cells
was changed, but not highly different from that of the interferon-g of an untreated
group, the T cells were not suitable for use as a blood sample. In the whole blood,
the PBMCs and the NK cells, there is a significant difference in amount of
interferon-g , compared to that of the interferon-g of the untreated group. Therefore,
the whole blood, the PBMCs and the NK cells were evaluated to be suitable blood
samples to apply to the method and kit according to the present invention.
Experimental Example 6: Comparison of NK Cell Activity from Normal
Persons by LPS
As another example of the agent that serves to stimulate NK cells in a
blood sample and artificially activate the NK cells to generate interferon-g , LPS was
used to measure an amount of interferon-g from human whole blood. As shown in
it was revealed that secretion of interferon-g was induced by 50 ng/ml of LPS,
which indicates that the NK cells may be artificially activated to generate the
interferon-g even when the NK cells are stimulated with a non-specific agonist such
as LPS.
Experimental Example 7: Stimulation of NK Cells by hIL12 and hIL15 fused
with Stabilizing peptide
As a tube for incubating NK cells, a tube (BD) containing an
anticoagulant, sodium heparin, was purchased and used to prevent coagulation of
blood. 5 ml of whole blood was taken and put into the tube containing the
anticoagulant (sodium heparin). 1 ml of the obtained whole blood was mixed with
RPIM1640 medium, and activators of NK cells, SP-hIL2/hIL12 were added thereto.
The resultant mixture was incubated at 37 °C for 16 to 24 hours. The stimulation
of the NK cells in the whole blood by the SP hIL2 fused with the stabilizing peptide
and hIL12 was determined by measuring an amount of the interferon-g in blood
incubated according to the method described in the above Experimental Example.
Meanwhile, the amount of the interferon-g secreted according to the
culture conditions of the whole blood was measured.. As shown in it was
revealed that the interferon-g secretion capability of the NK cells was increased
when the NK cells were incubated in PBS supplemented with a carrier protein such
as bovine serum albumin, compared to when the NK cells were incubated in PBS.
Experimental Example 8: Difference of interferon-g secretion according to
the progress stage of cancer
In order to determine an amount of the interferon-g secreted according to
the progress stage of cancer, whole blood from cancer patient 1 (a patient completely
recovered from breast cancer), cancer patient 2 (a patient suspected of suffering from
brain cancer), and a normal person was incubated for 24 hours in RPMI1640
medium supplemented with 100 ng/ml of IL12 and 1000 ng/ml of IL15, and amounts
of the secreted interferon-g were measured as described above. Also, the whole
blood was subjected to flow cytometry.
As a result, the interferon-g secretion capabilities were confirmed in
order of the normal person, the cancer patient 1 and the cancer patient 2, as shown in
. Therefore, it was confirmed that the amounts of interferon-g secreted
according to the progress stage of cancer were different. From these facts, it was
seen that the method according to the present invention may be used to measure an
amount of the interferon-g secreted by the NK cells in the blood sample, thereby
predicting the incidence and progress stage of cancer, or predicting the relapse of
cancer.
Experimental Example 9; Quantification of Interferon-g Generated by
Stimulation of NK Cells
As a tube for incubating NK cells, a tube (BD) containing an
anticoagulant, sodium heparin, was purchased and used to prevent coagulation of
blood. 5 ml of whole blood was taken from eight normal persons and put into the
tube containing the anticoagulant (sodium heparin). 1 ml of the obtained whole blood
was mixed with RPIM1640 medium, and SP-hIL12/hIL15-SP bound to stabilizing
peptide were added thereto. The resultant mixture was incubated at 37 °C for 16 to
24 hours.
Whole blood from eight normal persons incubated at 37 °C was
centrifuged at 1500 to 2000 g to obtain serum as a supernatant. Then, 150 to 200
ul of the serum was taken and subjected to interferon-g ELISA. 0.05% Tween
primary antibody (anti-human interferon-g monoclonal antibody, ATGen Cat#
ATGK02) was diluted with a coating buffer (0.1 sodium carbonate, pH 9.5) at a ratio
of 1:1000. The diluted primary antibody was divided onto a 96-well microtiter
ELISA plate (Nunc Maxisorp; NUNC, Naperville, IL) at a dose of 100 ul/well, and
kept at 4 °C for 16 to 18 hours. Thereafter, a solution in the plate was removed,
and the plate was washed with a washing solution (PBS containing 0.05% Tween 20)
at a dose of 400 ul/well. In this case, the washing was performed three times.
Then, PBS containing 10% fetal bovine serum (FBS) was divided at a dose of 300
ul/well, and kept at room temperature for 1 hour. Thereafter, a solution in the plate
was removed, and the plate was washed with PBST (a PBS solution containing
0.05% Tween 20) at a dose of 400 ul/well. In this case, the washing was
performed three times. The 96-well microtiter ELISA plate coated with the
primary antibody was sealed, and stored at 4 °C for use.
An interferon-g standard solution (PBS containing 200 ng of
recombinant human interferon-g (ATGen, Cat# IFG4001) and 0.05% Proclin 300)
was diluted and divided at a dose of 100 ul/well into the 96-well microtiter ELISA
plate coated with the primary antibody, and the patient's serum prepared in the
experimental stage was divided at a dose of 100 ul/well, and then kept at room
temperature for 2 hours.
Table 2
Blank: buffer only, S1-S6: serially di uted standard, and UK (unknown): patient
serum
After 2 hours, a solution in the 96-well microtiter ELISA plate was
removed, and the plate was washed with a washing solution at a dose of 400 ul/well.
In this case, the washing was performed three times. Then, a secondary antibody
(biotinylated anti-human interferon-g monoclonal antibody (ATGen Cat# ATGK03))
was diluted with a dilute solution at a ratio of 1:500, divided at a dose of 100 ul/well,
and then kept at room temperature for 1 hour. Thereafter, solution in the plate was
removed, and the plate was washed three times with a washing solution at a dose of
400 ul/well. An HRP-conjugated streptavidin solution (Thermo Scientific, Cat#
2 1130) was diluted with a dilute solution at a ratio of 1:3000, divided at a dose of
100 ul/well, and then kept at room temperature for 30 minutes. Then, the diluted
HRP-conjugated streptavidin solution was divided into the ELISA plate, and
incubated for 1 hour. After the one-hour incubation, a solution in the 96-well
microtiter ELISA plate was removed, and the plate was washed three times with a
washing solution at a dose of 400 ul/well.
1 mg of tetramethylbenzidine (TMB) was dissolved in 1 ml of
dimethylsulfoxide (DMSO), and the resultant mixture was diluted with 9 ml of 0.05
M phosphate citrate buffer to prepare a substrate solution. Then, the substrate
solution was divided into the plate at a dose of 100 ul/well, and kept at room
temperature for 30 minutes.
A reaction-stopping solution (a 2 N dilute sulfuric acid solution) was
divided at a dose of 100 ul/well to stop the reaction, and the resultant reaction
solution was measured at 450 n using an ELISA reader.
[001 10] The interferon-g secretion capabilities of the NK cells measured using
the whole blood from eight normal persons are shown in . These results
indicate that, when the whole blood is stimulated by the cytokine, immune cells
present in blood are effectively activated to induce secretion of interferon- g .
[001 11] Furthermore, after the whole blood from the eight normal persons was
stimulated by the cytokine, the whole blood was subjected to flow cytometry. The
results are shown in . From these results, it was revealed that the NK cells
expressed cytotoxicity as the NK cells were activated by the stimulation of the whole
blood. CD56 is a marker of the NK cells, and CD 107a is a marker indicating that
the NK cells secrete cytotoxic granules. Since the results of secretion of the
interferon- g of significantly correlate with the cytotoxicity results by the NK
cells of , it was seen that the interferon-g secretion capability of the NK cells
by the stimulation of the whole blood indirectly expresses the cytotoxicity of the NK
cells.
[001 12] According to the present invention, the incidence or relapse of cancer
may be diagnosed by monitoring changes in an in vivo immune system and
measuring NK cell activity in blood, for instance in a subject with or suspected of
having cancer. The present invention may therefore be useful in predicting the
incidence or relapse of cancer using a blood sample from a subject.
[001 13] While exemplary embodiments have been disclosed herein, it should be
understood that other variations may be possible. Such variations are not to be
regarded as a departure from the scope of exemplary embodiments of the present
application, and all such modifications as would be obvious to one skilled in the art
are intended to be included within the scope of the following claims.
[001 14] All documents cited herein are hereby incorporated by reference.
Claims (25)
1. A method of measuring NK cell activity, comprising: stimulating NK cells in a whole blood sample thereby artificially activating the NK cells to generate NK cell-secreting cytokines; and measuring an amount of the NK cell-secreting cytokines in the whole blood sample.
2. The method according to claim 1, wherein the stimulation of the NK cells is performed by incubating the whole blood sample with a stimulating cytokine.
3. The method according to claim 1, wherein the stimulation of the NK cells is performed by incubating the whole blood sample with at least one stimulating cytokine selected from the group consisting of interleukin 2, interleukin 12, interleukin 15 and interleukin 18, or by incubating the whole blood sample with lipopolysaccharides (LPSs) or polyinosinic:polycytidylic acid (poly I:C).
4. The method according to claim 1, wherein the stimulation of the NK cells is performed by incubating the whole blood sample with interleukin 2.
5. The method according to claim 1, wherein the stimulation of the NK cells is performed by incubating the whole blood sample with interleukin 2 and interleukin 12.
6. The method according to claim 1, wherein the stimulation of the NK cells is performed by incubating the whole blood sample with interleukin 12 and interleukin 15.
7. The method according to claim 1, wherein the stimulation of the NK cells is performed by incubating the whole blood sample with interleukin 12 and interleukin 18.
8. The method according to claim 1, wherein the NK cell-secreting cytokines are selected from the group consisting of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α) and macrophage inflammatory protein-1β (ΜΙΡ-1β).
9. The method according to claim 1, wherein macrophage inflammatory protein-1β (MIP-1β) is used as control group for comparing activation of NK cells with that of a normal person.
10. The method according to claim 1, wherein the measuring of the amount of the NK cell- secreting cytokines is performed by an immuno-assay such as an enzyme-linked immunosorbent assay (ELISA).
11. The method according to claim 3, wherein the at least one stimulating cytokine is in the form of a fusion protein with a stabilizing peptide.
12. The method according to claim 11, wherein the stabilizing peptide is a C-terminal acidic tail domain peptide of a synuclein family.
13. The method according to claim 12, wherein the stabilizing peptide comprises amino acid residues 103-115 (SEQ ID NO: 22), amino acid residues 114-126 (SEQ ID NO: 23), amino acid residues 119-140 (SEQ ID NO: 24) or amino acid residues 130-140 (SEQ ID NO: 25) of the C- terminal acidic tail domain of α-synuclein, amino acid residues 85-134 of the C-terminal acidic tail domain of β-synuclein (SEQ ID NO: 27), amino acid residues 1-127 of γ-synuclein (SEQ ID NO: 28), or amino acid residues 96-127 of the C-terminal acidic tail domain of γ-synuclein (SEQ ID NO: 29).
14. The method according to claim 1, wherein the step of stimulating NK cells in a whole blood sample thereby artificially activating the NK cells to generate NK cell-secreting cytokines is performed in solution (lyophilized or liquid) containing a carrier protein.
15. Use of at least one stimulating cytokine, lipopolysaccharide (LPS) or polyinosinic:polycytidylic acid (poly I:C) in the manufacture of a kit for measuring NK cell activity, wherein said at least one stimulating cytokine, lipopolysaccharide (LPS) or polyinosinic:polycytidylic acid (poly I:C) is provided for stimulating NK cells in a whole blood sample and thereby artificially activating the NK cells to generate NK cell-secreting cytokines, and wherein an amount of the NK cell-secreting cytokines in the whole blood sample is used to measure NK cell activity .
16. The use according to claim 15, wherein the NK cell-secreting cytokine is interferon-gamma (IFN-γ).
17. The use according to claim 15, wherein the NK cell-secreting cytokine is tumor necrosis factor-alpha (TNF-α).
18. The use according to claim 15, wherein the at least one stimulating cytokine is selected from the group consisting of interleukin 2, interleukin 12, interleukin 15 and interleukin 18.
19. The use according to claim 15, wherein the kit further comprises at least one antibody selected from the group consisting of an anti-IFN-γ antibody, an anti-TNF-α antibody and an anti-MIP-1β antibody.
20. The use according to claim 18, wherein the at least one stimulating cytokine is provided as a fusion protein bound to a C-terminal acidic tail domain peptide of a synuclein family.
21. The use according to claim 20, wherein the at least one stimulating cytokine is interleukin 2.
22. The use according to claim 20, wherein the at least one stimulating cytokine is interleukin 12.
23. The use according to claim 20, wherein the at least one stimulating cytokine is interleukin 15.
24. The use according to claim 20, wherein the at least one stimulating cytokine is interleukin 18.
25. The use according to any one of claims 20 to 24, wherein the C-terminal acidic tail domain peptide of the synuclein family is selected from the group consisting of amino acid residues 103- 115 (SEQ ID NO: 22), amino acid residues 114-126 (SEQ ID NO: 23), amino acid residues 119- 140 (SEQ ID NO: 24) and amino acid residues 130-140 (SEQ ID NO: 25) of the C-terminal acidic tail domain of α-synuclein, amino acid residues 85-134 of the C-terminal acidic tail domain of β-synuclein (SEQ ID NO: 27), amino acid residues 1-127 of γ-synuclein (SEQ ID NO: 28), and amino acid residues 96-127 of the C-terminal acidic tail domain of γ-synuclein (SEQ ID NO: 29). 921046wo_ST25.txt
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ710432A NZ710432B2 (en) | 2011-02-14 | 2012-02-10 | Method and use for measurement of nk cell activity |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110012983A KR20120093002A (en) | 2011-02-14 | 2011-02-14 | Method for diagnosing cancer and diagnosis kit using measurement of nk cell activity |
KR10-2011-0012983 | 2011-02-14 | ||
PCT/IB2012/000259 WO2012110878A2 (en) | 2011-02-14 | 2012-02-10 | Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ614345A NZ614345A (en) | 2015-09-25 |
NZ614345B2 true NZ614345B2 (en) | 2016-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220229070A1 (en) | Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity | |
JP2016507748A (en) | Autoantibody signature for early detection of ovarian cancer | |
JPWO2008001944A1 (en) | Reagent for detecting autoantibody and diagnostic kit for autoimmune disease | |
WO2013080811A1 (en) | Biomarker for lymphocytic infundibuloneurohypophysitis, and use applications thereof | |
NZ614345B2 (en) | Method and use for measurement of nk cell activity | |
NZ710432B2 (en) | Method and use for measurement of nk cell activity | |
EP3436828A1 (en) | Marker sequences for rheumatoid arthritis | |
EP2606361B1 (en) | A novel method for diagnosing q-fever using a cellular immunological test | |
JP6607436B2 (en) | Novel MPO-ANCA test method to identify pathological conditions of intractable vasculitis | |
JP2022182394A (en) | Antigen-immobilized device | |
WO2024036134A2 (en) | Defensin proteins for infection assessment |